ライフサイエンスコーパス: primary disease

1 There was no difference in survival based on primary disease.

2 ong 27 patients who presented with localized primary disease.

3 compared with normal controls and those with primary disease.

4 exhibit all the pathological features of the primary disease.

5 oportionately worse prognosis than localized primary disease.

6 detected in approximately 13% of adults with primary disease.

7 ricted to surveillance for recurrence of the primary disease.

8 xpressed differentially in metastatic versus primary disease.

9 and predicts a poor outcome in patients with primary disease.

10 B, or HER2-E signatures in metastatic versus primary disease.

11 ide guidance for follow-up of the survivor's primary disease.

12 6 (72.3%) were attributable to the patient's primary disease.

13 imaging for both biochemical recurrence and primary disease.

14 reviewed to identify patients with recurrent primary disease.

15 on, hepatic artery thrombosis, and recurrent primary disease, 180 required dialysis, and 45 underwent

16 ian survival was 72 months for patients with primary disease, 28 months for those with local recurren

17 Relapse of primary disease (29%) and chronic graft-versus-host dise

18 Relapse of primary disease (56%) and subsequent malignancies (25%)

19 atients aged 7-18 years (27 with mediastinal primary disease) after primary treatment.

20 Two hundred seventy-eight patients (56%) had primary disease and 222 (44%) recurrent disease.

21 This was out of a total of 115 patients with primary disease and 91 patients with recurrent disease.

22 radiotherapy and chemotherapy (aRCeBCSs) for primary disease and a population-based reference group.

23 provided by their application to SV, in both primary disease and connective tissue diseases (CTD), is

24 y achieving margin-negative resection of the primary disease and delivering effective adjuvant and/or

25 sis was performed for patients with T1 or T2 primary disease and one to three involved nodes (n = 404

26 CMV primary disease and reactivation greatly increase the ri

27 ts) could not be attributed to the patient's primary disease and thus were suspicious for an adverse

28 amples, RB loss was infrequently observed in primary disease and was predominantly associated with tr

29 year, cardiopulmonary events, recurrence of primary disease, and malignancy were the main causes of

30 Age-related complications, recurrence of primary disease, and malignancy were the major causes of

31 ons during the development from precursor to primary disease, and primary testicular GCTs (TGCTs) are

32 thrombocytopenic purpura focused entirely on primary disease, and secondary forms were not addressed.

33 omography/CT is limited in the assessment of primary disease but is gaining acceptance in prostate ca

34 Many of these factors have been defined for primary disease, but relatively few have been investigat

35 resence of chromosomal rearrangements as the primary disease cause.

36 The challenge remains to separate primary disease-causing factors from secondary disease-m

37 Collectively, these data identify a primary disease-causing molecular defect in cone cells a

38 Variable expression, independently from the primary disease-causing mutation, can partly be explaine

39 Factors such as primary disease, chronic graft-vs-host disease, prolonge

40 signature was better at predicting OSmet in primary disease compared with metastatic tissue.

41 ng female patients with cancer survive their primary disease, concerns about reproductive health rela

42 yte function at a molecular level may be the primary disease determinant, with noncompaction arising

43 These comprise general effects of the primary disease, e.g., inflammatory state, more specific

44 int, invasive-disease-free survival, was the primary disease endpoint for the analysis in this report

45 ge of patients are at risk for recurrence of primary disease following lung transplantation.

46 related diseases, even if they do not share primary disease genes.

47 In cases of unknown primary disease, genetic fingerprints can be used to def

48 mortality from 100% to 45% (P<0.0001) in the primary disease hamster model and from 78% to 32% (P<0.0

49 Results clearly indicate that unlike primary disease, IL-6 plays no role in recurrent HSK.

50 Relapse occurred at the site of primary disease in 10 patients, at a distant site in thr

51 radial margin positivity (RMP) is defined as primary disease involvement at the cut edge of the mesen

52 attributable to recurrence or progression of primary disease is decreasing, with increases in rates o

53 disease similar to that of human infection: primary disease, latent infection, and reactivation tube

54 ences resulting from permanent damage by the primary disease, LCH (eg, diabetes insipidus, fractures,

55 ertion in RPGRIP1 (RPGRIP1 (ins/ins)) as the primary disease locus while a homozygous deletion in MAP

56 Excision of the primary disease, lymph node metastases, and in some inst

57 temporal trends in clinical presentation and primary disease management among patients with low-risk

58 n of therapy, which have negative effects on primary disease management.

59 Treatment of the primary disease may be curative in some patients.

60 raising the possibility that it represents a primary disease mechanism and not a secondary hypoxia-in

61 icrotubule cytoskeleton, is likely to be the primary disease mechanism in HSP caused by missense muta

62 f the neuromuscular junction is considered a primary disease mechanism in human myasthenia gravis and

63 due to defective N-linked glycosylation is a primary disease mechanism in this disorder.

64 CHR) (n=44), IF/TA (n=42), recurrence of the primary disease (n=11), de novo glomerulonephritis (n=7)

65 icity, n=4; urinary leak, n=2; recurrence of primary disease, n=1; lymphocele, n=1; and unknown, n=1.

66 amilial hypertrophic cardiomyopathy (FHC), a primary disease of heart muscle.

67 Primary disease of the gland is never separated from the

68 Castleman's disease is a rare primary disease of the lymph node caused by infection wi

69 ARVC is a primary disease of the myocardium characterized by fibro

70 oles in the milieu of diseases including the primary diseases of myelin.

71 ng progression of neurological disability in primary diseases of myelin.

72 ysiology of cardiac ischemia and infarction, primary diseases of the myocardium, and the effects of v

73 EBV, however, may result in severe primary disease or cancer.

74 me of Mtb infection, defining progression to primary disease or latent infection and reactivated tube

75 DSS at 10 years was 31.6% for 87 primary disease patients, 25.9% for 26 recurrent patient

76 A first step in primary disease prevention is identifying common, modifi

77 balance the benefits and harms of aspirin in primary disease prevention, the Task Force issued a guid

78 ed for evidence-based dietary guidelines for primary disease prevention.

79 The primary disease process in myelofibrosis with myeloid me

80 These differences may reflect a primary disease process in this area or be secondary eff

81 not known whether this neuronal damage is a primary disease process, or occurs only secondary to dem

82 teractions among many factors, including the primary disease process, use of medications such as cort

83 ransplant-/infection-related (n = 3), due to primary disease progression in advanced adult cerebral a

84 Five patients died of primary disease progression within 6 months after stent

85 d death but appears to be a marker of severe primary disease rather than an independent predictor of

86 e acute GVHD while retaining protection from primary disease relapse and infectious complications.

87 e pretreatment with medroxyprogesterone, and primary disease resembles that observed in humans.

88 e craniospinal axis (RR 1.6), and relapse of primary disease (RR 3.5) to be independently associated

89 egulatory consequences of non-coding SNPs in primary disease samples.

90 only due to chronic rejection, recurrence of primary disease, sepsis, lympho-proliferative disease, o

91 tors for poor socioprofessional outcome were primary disease severity (onset in infancy or hereditary

92 Three of 5 patients with primary disease showed positive tumor delineation in the

93 ication factors were WHO performance status, primary disease site, and stage.

94 Unfavorable primary disease site, nodal involvement at diagnosis, al

95 e stratification factors: extent of disease, primary disease site, previous treatment, ECOG performan

96 etation of future trials should consider the primary disease states of patients and the balance of me

97 Linkage studies have clearly identified a primary disease susceptibility locus lying within the ma

98 After resolution of the primary disease, SVV and VZV establish latent infection

99 positive, 18-65 years old, without high-risk primary disease, T-cell depletion, previous vaccination

100 By standard histopathology, 7 patients had primary disease that was either benign or not colon canc

101 ne deficiency (CVID) is an assorted group of primary diseases that clinically manifest with antibody

102 Patients whose primary disease was arthritis were randomized to the ASM

103 icity, urological problems, or recurrence of primary disease were remarkable for the lack of expressi

104 verses portal hypertension and addresses the primary disease while achieving superior survival result

105 s disease-specific survival in patients with primary disease who undergo complete gross resection.

106 In patients with primary disease who underwent complete resection of gros

107 conveyed nearly complete protection against primary disease with either virus but did not prevent mu

108 atment of myelomatous SCID-hu mice, carrying primary disease, with recombinant Wnt3a stimulated bone

109 Of the 200 patients, 46% had primary disease without metastasis, 47% had metastasis,